Non-Hodgkin's Lymphoma: Review of Conventional Treatments

Authors: Multani P.; White C.A.; Grillo-Lopez A.

Source: Current Pharmaceutical Biotechnology, Volume 2, Number 4, December 2001 , pp. 279-291(14)

Publisher: Bentham Science Publishers

Abstract:

The non-Hodgkin's lymphomas are a diverse groups of lymphoid neoplasms that collectively rank fifth in cancer incidence and mortality. Conventional treatment for patients with newly-diagnosed non-Hodgkin's lymphoma (NHL) includes radiation or chemotherapy. In addition, those with asymptomatic low-grade disease may follow a “watch and wait” approach. Single agent oral alkylating therapy and CVP (cyclophosphamide, vincristine, and prednisone) have become a mainstay of treatment for low-grade NHL. High intensity chemotherapy consisting of the anthracycline, doxorubicin along with cyclophosphamide, vincristine and prednisone (CHOP) is offered as standard treatment for intermediate-grade NHL. Following relapse, salvage therapy rarely results in long-term survival in patients with low-grade NHL. Up to 50percent of patients die within five years of first relapse. For patients with intermediate-grade NHL who relapse after or do not respond to first-line treatment, a range of combination regimens can be offered, composed of non-cross resistant drugs not typically used during first-line treatment. However, less than half of patients with intermediate-grade disease achieve prolonged disease-free survival. With today‘s’conventional treatments, cure is only a possibility for a minority of patients with intermediate-grade disease and a limited group of patients with indolent NHL who are diagnosed at early stages. Novel approaches to treatment are therefore needed. Monoclonal antibodies may fulfill this need, administered either as single agents or in conjunction with conventional cytotoxic approaches. The task now lies in determining how best to use this new modality, with the hope of bringing a cure to a greater number of patients.

Keywords: lymphoid neoplasms; non-Hodgkins lymphomas; Monoclonal antibodies; newly-diagnosed NHL; chorambucil or cyclophosphamide; Anthracycline-Based Regimens; Fludarabine; Acquired immunodeficiency syndrome; Computed tomography

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201013378581

Publication date: 2001-12-01

• Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

• In this: publication
• By this: publisher
• In this Subject: Nutrition & Food ,  Biotechnology ,  Pharmacology
• By this author: Multani P. ;  White C.A. ;  Grillo-Lopez A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers